Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 12Small Cell Lung Carcinoma 5Nonsquamous Non-Small Cell Lung Cancer 2Neoplasms 2Carcinoma 2Advanced Lung Cancer 2Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Cancer Extensive Stage 1SCLC 1Respiratory Tract Diseases 1Resectable Non-small Cell Lung Cancer 1Resectable NSCLC 1Radiation Pneumonitis 1Osteosarcoma 1Non-small Cell Lung Cancer Metastatic 1Non-Squamous Non-Small Cell Lung Cancer 1NSCLC 1Multiple Primary Lung Cancer 1Lung Diseases 1Locally Advanced Non-Small Cell Lung Cancer 1IIIA Stage Non-small Cell Lung Cancer 1High-Risk Resectable NSCLC 1Brain Neoplasms 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Docetaxel 6Gemcitabine 3Carboplatin 3lorlatinib 2cemiplimab 2Vinorelbine 2S 1 (combination) 2Pemetrexed 2Erlotinib Hydrochloride 2Cisplatin 2Cetuximab 2zimberelimab 1surufatinib 1sintilimab 1quemliclustat 1pemigatinib 1pembrolizumab 1nimotuzumab 1fludarabine 1WW Domain-Containing Oxidoreductase 1Paclitaxel 1Interleukin-2 1Gene Expression Profiling 1Drug Therapy 1Cyclophosphamide 1Capecitabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non-Small Cell Lung Cancer × sintilimab × Thoracic × Clear all
NCT05504278 2025-01-27

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
144 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡